Role of HIV-1 Tat in AIDS pathogenesis: Its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection

AIDS

Volumn 24, Issue 11, 2010, Pages 1609-1623

  Li, James Chun Bong ^a   Yim, Howard Chi Ho ^a   Lau, Allan Sy ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLORO 1,3 DIHYDRO 5 (2 PYRROLYL) 2H 1,4 BENZODIAZEPIN 2 ONE; [7 CHLORO 5 (1H PYRROL 2 YL) 3H BENZO[E][1,4]DIAZEPIN 2 YL]METHYLAMINE; ALPHA INTERFERON; CYCLOPENTENONE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SURAMIN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CANCER; B CELL LYMPHOMA; CANDIDA ALBICANS; CYTOKINE PRODUCTION; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DYSREGULATION; KAPOSI SARCOMA; LEISHMANIA; LEISHMANIASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED INFECTION; MOUTH CANCER; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VIRUS REPLICATION; VIRUS SURVIVAL; VIRUS TRANSCRIPTION; WART VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CYTOKINES; HIV-1; HUMANS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77954322304     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ac6a0     Document Type: Review

References (169)

1. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375:497-500.
2. Myers G, Korber BT, Foley BT, Jeang K-T, Mellors JW, Wain-Hobson S, editors. Human retroviruses and AIDS 1996: A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 1996. pp. III-11-III-16.
3. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 1999; 274: 28837-28840.
4. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19:1173-1176.
5. Berry CC. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine 2008; 3:357-365.
6. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005; 57:579-596.
7. Cann AJ, Rosenblatt JD, Wachsman W, Shah NP, Chen IS. Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation. Nature 1985; 318:571-574.
8. Mahlknecht U, DichampI, Varin A, Van Lint C, Herbein G. NF-kappaB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells. J Leukoc Biol 2008; 83:718-727.
9. Sune C, Garcia-Blanco MA. Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat. J Virol 1995; 69:6572-6576.
10. Mukerjee R, Sawaya BE, Khalili K, Amini S. Association of p65 and C/EBPbeta with HIV-1 LTR modulates transcription of the viral promoter. J Cell Biochem 2007; 100:1210-1216.
11. King JE, Eugenin EA, Buckner CM, Berman JW. HIV tat and neurotoxicity. Microbes Infect 2006; 8:1347-1357.
12. Yim HC, Li JC, Lau JS, Lau AS. HIV-1 Tat dysregulation of lipopolysaccharide-induced cytokine responses: microbial interactions in HIV infection. AIDS 2009; 23:1473-1484.
13. Li JC, Lee DC, Cheung BK, Lau AS. Mechanisms for HIV Tat upregulation of IL-10 and other cytokine expression: kinase signaling and PKR-mediated immune response. FEBS Lett 2005; 579:3055-3062.
14. Li JC, Lau AS. A role for mitogen-activated protein kinase and Ets-1 in the induction of interleukin-10 transcription by human immunodeficiency virus-1 Tat. Immunology 2007; 121:337-348.
15. Gandhi N, Saiyed Z, Thangavel S, Rodriguez J, Rao KV, Nair MP. Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflamma-tory cytokines by primary monocytes. AIDS Res Hum Retro-viruses 2009; 25:691-699.
16. Desfosses Y, Solis M, Sun Q, Grandvaux N, Van Lint C, Burny A, et al. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J Virol 2005; 79:9180-9191.
17. Campbell GR, Watkins JD, Singh KK, Loret EP, Spector SA. Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol 2007; 81:5919-5928.
18. Ranga U, Shankarappa R, Siddappa NB, Ramakrishna L, Na-gendran R, Mahalingam M, et al. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 2004; 78:2586-2590.
19. Samikkannu T, Saiyed ZM, Rao KV, Babu DK, Rodriguez JW, Papuashvili MN, Nair MP. Differential regulation of indolea-mine-2, 3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses 2009; 25:329-335.
20. Campbell GR, Loret EP, Spector SA. HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4R T cells. J Biol Chem, 2010; 285:1681-1691.
21. Belardelli F. Role of interferons and other cytokines in the regulationofthe immuneresponse. APMIS 1995; 103:161-179.
22. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M. Inflammatory cytokines and systemic-onset juvenile idio-pathic arthritis. Mod Rheumatol 2004; 14:12-17.
23. Cross JT, Benton HP. The roles of interleukin-6 and interleu-kin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res 1999; 48:255-261.
24. Peters M, Muller AM, Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and he-matopoiesis. Blood 1998; 92:3495-3504.
25. Zauli G, Furlini G, Re MC, Milani D, Capitani S, La Placa M. Human immunodeficiency virus type 1 (HIV-1) tat-protein stimulates the production of interleukin-6 (IL-6) by peripheral blood monocytes. New Microbiol 1993; 16:115-120.
26. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 1990; 9:1897-1906.
27. Coyle-Rink J, Sweet T, Abraham S, Sawaya B, Batuman O, Khalili K, Amini S. Interaction between TGFbeta signaling proteins and C/EBP controls basal and Tat-mediated transcription of HIV-1 LTR in astrocytes. Virology 2002; 299:240-247.
28. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F, Trematerra S, et al. HIV-1 Tat induces the expression of the interleukin-6(IL6) genebybindingtothe IL6 leader RNAandby interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 1997; 272:14883-14892.
29. Lee YW, Hirani AA, Kyprianou N, Toborek M. Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells. Inflamm Res 2005; 54:380-389.
30. Zidovetzki R, Wang JL, Chen P, Jeyaseelan R, Hofman F. Human immunodeficiency virus Tat protein induces inter-leukin 6 mRNA expression in human brain endothelial cells via protein kinase C-and cAMP-dependent protein kinase pathways. AIDS Res Hum Retroviruses 1998; 14:825-833.
31. Sui Z, Fan S, Sniderhan L, Reisinger E, Litzburg A, Schifitto G, et al. Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J Immunol 2006; 177:702-711.
32. Toschi E, Bacigalupo I, Strippoli R, Chiozzini C, Cereseto A, Falchi M, et al. HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. Mol Biol Cell 2006; 17:1985-1994.
33. Peruzzi F, Gordon J, Darbinian N, Amini S. Tat-induced deregulation of neuronal differentiation and survival by nerve growth factor pathway. J Neurovirol 2002; 8 (Suppl 2):91-96.
34. McMillan NA, Chun RF, Siderovski DP, Galabru J, Toone WM, Samuel CE, et al. HIV-1 Tat directly interacts with the inter-feron-induced, double-stranded RNA-dependent kinase, PKR. Virology 1995; 213:413-424.
35. Demarchi F, Gutierrez MI, Giacca M. Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J Virol 1999; 73:7080-7086.
36. Endo-Munoz L, Warby T, Harrich D, McMillan NA. Phosphor-ylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription. Virol J 2005; 2:17.
37. Mesri EA. Inflammatory reactivation and angiogenicity of Kaposi?s sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi?s sarcoma. Blood 1999; 93:4031-4033.
38. Yeung MC, Chang DL, Camantigue RE, Lau AS. Inhibitory role of the host apoptogenic gene PKR in the establishment of persistent infection by encephalomyocarditis virus in U937 cells. Proc Natl Acad Sci USA 1999; 96:11860-11865.
39. Yeung MC, Liu J, Lau AS. An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. Proc Natl Acad Sci USA 1996; 93:12451-12455.
40. Bennasser Y, Badou A, Tkaczuk J, Bahraoui E. Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-alpha. Virology 2002; 303:174-180.
41. Leghmari K, Contreras X, Moureau C, Bahraoui E. HIV-1 Tat protein induces TNF-alpha and IL-10 production by human macrophages: differential implication of PKC-betaII and-delta isozymes and MAP kinases ERK1/2 and p38. Cell Immunol 2008; 254:46-55.
42. Mayne M, Holden CP, Nath A, Geiger JD. Release of calcium from inositol 1, 4, 5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-alpha production in human macro-phages. J Immunol 2000; 164:6538-6542.
43. Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, Dewhurst S, Maggirwar SB. Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol 2007; 178:3226-3236.
44. McCloskey TW, Ott M, Tribble E, Khan SA, Teichberg S, Paul MO, et al. Dual role of HIV Tat in regulation of apoptosis in T cells. J Immunol 1997; 158:1014-1019.
45. Fiorentino DF, Bond MW, Mosmann TR. Two typesofmouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081-2095.
46. Chan MM, Cheung BK, Li JC, Chan LL, Lau AS. A role for glycogen synthase kinase-3 in antagonizing mycobacterial immune evasion by negatively regulating IL-10 induction. J Leukoc Biol 2009; 86:283-291.
47. Brightbill HD, Plevy SE, Modlin RL, Smale ST. A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J Immunol 2000; 164:1940-1951.
48. Tone M, Powell MJ, Tone Y, Thompson SA, Waldmann H. IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol 2000; 165:286-291.
49. Gee K, Angel JB, Mishra S, Blahoianu MA, Kumar A. IL-10 regulation by HIV-Tat in primary human monocytic cells: involvement of calmodulin/calmodulin- dependent protein kinase-activated p38 MAPK and Sp-1 and CREB-1 transcription factors. J Immunol 2007; 178:798-807.
50. Powell MJ, Thompson SA, Tone Y, Waldmann H, Tone M. Posttranscriptional regulation of IL-10 gene expression through sequences in the 3?-untranslated region. J Immunol 2000; 165:292-296.
51. Leghmari K, Bennasser Y, Bahraoui E. HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways. Eur J Cell Biol 2008; 87:947-962.
52. Crawley E, Woo P, Isenberg DA. Single nucleotide polymorphic haplotypes of the interleukin-10 5 flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42:2017-2018.
53. Rosenwasser LJ, Borish L. Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). Am J Respir Crit Care Med 1997; 156:S152-S155.
54. Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O?Brien SJ, et al. Non-Hodgkin?s B cell lymphoma in persons with acquired immunodeficiency syndromeis associated with increased serum levels of IL10, or the IL10 promoter S592 C/C genotype. Clin Immunol 2003; 109:119-129.
55. Kollmann TR, Pettoello-Mantovani M, Katopodis NF, Hacha-movitch M, Rubinstein A, Kim A, Goldstein H. Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. Proc Natl Acad Sci USA 1996; 93:3126-3131.
56. ScholsD, De ClercqE. Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production. J Virol 1996; 70:4953-4960.
57. Than S, Hu R, Oyaizu N, Romano J, Wang X, Sheikh S, Pahwa S. Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children. J Infect Dis 1997; 175:47-56.
58. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000; 97:14467-14472.
59. Breen EC. Pro-and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. Pharmacol Ther 2002; 95:295-304.
60. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O?Garra A. IL-10 inhibits cytokine production by activated macro-phages. J Immunol 1991; 147:3815-3822.
61. Hsu DH, Moore KW, Spits H. Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. Int Immunol 1992; 4:563-569.
62. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220.
63. Moore KW, de Waal Malefyt R, Coffman RL, O?Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
64. Gringeri A, Santagostino E, Cusini M, Muca-Perja M, Marinoni A, Mannucci PM, et al. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active antiinterferon-alpha immunization: a 30-month follow-up report. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:55-67.
65. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, et al. Interferon alpha and Tat involvement in the immuno-suppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95:3851-3856.
66. Pauza CD, Trivedi P, Wallace M, Ruckwardt TJ, Le Buanec H, Lu W, et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 2000; 97:3515-3519.
67. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, San-chez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-F36.
68. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
69. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
70. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apop-tosis 2003; 8:237-249.
71. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778-809.
72. Young HA, Hardy KJ. Role of interferon-gamma in immune cell regulation. J Leukoc Biol 1995; 58:373-381.
73. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5:375-386.
74. Chan LL, Cheung BK, Li JC, Lau AS. A role for STAT3 and cathepsin S in IL-10 downregulation of IFN-gamma-induced MHC class II molecule on primary human blood macro-phages. J Leukoc Biol 2010 Mar 31. [Epub ahead of print]
75. Giunta B, Obregon D, Hou H, Zeng J, Sun N, Nikolic V, et al. EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of JAK/STAT1 signaling and implications for HIV-associated dementia. Brain Res 2006; 1123:216-225.
76. Meylan PR, Guatelli JC, Munis JR, Richman DD, Kornbluth RS. Mechanisms for the inhibition of HIV replication by inter-ferons-alpha,-beta, and-gamma in primary human macro-phages. Virology 1993; 193:138-148.
77. Sarol LC, Imai K, Asamitsu K, Tetsuka T, Barzaga NG, Oka-moto T. Inhibitory effects of IFN-gamma on HIV-1 replication in latently infected cells. Biochem Biophys Res Commun 2002; 291:890-896.
78. Cheng SM, Li JC, Lin SS, Lee DC, Liu L, Chen Z, Lau AS. HIV-1 transactivator protein induction of suppressor of cytokine signaling-2 contributes to dysregulation of IFN{gamma} signaling. Blood 2009; 113:5192-5201.
79. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387:917-921.
80. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit inter-feron-mediated antiviral and antiproliferative activities. J Biol Chem 1998; 273:35056-35062.
81. Stoiber D, Kovarik P, Cohney S, Johnston JA, Steinlein P, Decker T. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J Immunol 1999; 163:2640-2647.
82. Dhillon N, Zhu X, Peng F, Yao H, Williams R, Qiu J, et al. Molecular mechanism(s) involved in the synergistic induction of CXCL10 by human immunodeficiency virus type 1 Tat and interferon-gamma in macrophages. J Neurovirol 2008; 14:196-204.
83. Gonzalez E, Punzon C, Gonzalez M, Fresno M. HIV-1 Tat inhibits IL-2 gene transcription through qualitative and quantitative alterations of the cooperative Rel/AP1 complex bound to the CD28RE/AP1 composite element of the IL-2 promoter. J Immunol 2001; 166:4560-4569.
84. Ehret A, Li-Weber M, Frank R, Krammer PH. The effect of HIV-1 regulatory proteins on cellular genes: derepression of the IL-2 promoter by Tat. Eur J Immunol 2001; 31:1790-1799.
85. Hidalgo-Estevez AM, Gonzalez E, Punzon C, Fresno M. Human immunodeficiency virus type 1 Tat increases cooperation between AP-1 and NFAT transcription factors in T cells. J Gen Virol 2006; 87:1603-1612.
86. Kutsch O, Oh J, Nath A, Benveniste EN. Induction of the chemokines interleukin-8 and IP-10 by human immunodeficiency virus type 1 tat in astrocytes. J Virol 2000; 74:9214-9221.
87. Ott M, Lovett JL, Mueller L, Verdin E. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors. J Immunol 1998; 160:2872-2880.
88. Mahieux R, Lambert PF, Agbottah E, Halanski MA, Deng L, Kashanchi F, Brady JN. Cell cycle regulation of human inter-leukin-8 gene expression by the human immunodeficiency virus type 1 Tat protein. J Virol 2001; 75:1736-1743.
89. Ito M, Ishida T, He L, Tanabe F, Rongge Y, Miyakawa Y, Terunuma H. HIV type 1 Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1998; 14:845-849.
90. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, Ensoli B. Native HIV-1 Tat protein targets mono-cyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 2002; 168:197-206.
91. Turchan-Cholewo J, Dimayuga VM, Gupta S, Gorospe RM, Keller JN, Bruce-Keller AJ. NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat. Antioxid Redox Signal 2009; 11:193-204.
92. Abraham S, Sweet T, Sawaya BE, Rappaport J, Khalili K, Amini S. Cooperative interaction of C/EBP beta and Tat modulates MCP-1 gene transcription in astrocytes. J Neuroimmunol 2005; 160:219-227.
93. Abraham S, Sawaya BE, Safak M, Batuman O, Khalili K, Amini S. Regulation of MCP-1 gene transcription by Smads and HIV-1 Tat in human glial cells. Virology 2003; 309:196-202. (Pubitemid 36579214)
94. Lim SP, Garzino-Demo A. The human immunodeficiency virus type 1 Tat protein up-regulates the promoter activity of the beta-chemokine monocyte chemoattractant protein 1 in the human astrocytoma cell lineU-87 MG: roleofSP-1, AP-1, and NF-kappaB consensus sites. J Virol 2000; 74:1632-1640.
95. Williams R, Yao H, Peng F, Yang Y, Bethel-Brown C, Buch S. Cooperative induction of CXCL10 involves NADPH oxidase: Implications for HIV dementia. Glia 2010; 58:611-621.
96. Popik W, Pitha PM. The presence of tat protein or tumor necrosis factor alpha is critical for herpes simplex virus type 1-induced expression of human immunodeficiency virus type 1. J Virol 1994; 68:1324-1333.
97. Schafer SL, Vlach J, Pitha PM. Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site. J Virol 1996; 70:6937-6946.
98. Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010; 120:939-949.
99. Harrington W Jr, Sieczkowski L, Sosa C, Chan-a-Sue S, Cai JP, Cabral L, Wood C. Activation of HHV-8 by HIV-1 tat. Lancet 1997; 349:774-775.
100. Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood 2004; 104:810-814.
101. Zeng Y, Zhang X, Huang Z, Cheng L, Yao S, Qin D, et al. Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi?s sarcoma-associated herpesvirus: role of JAK/STAT signaling. J Virol 2007; 81:2401-2417.
102. Huang LM, Chao MF, Chen MY, Shih H, Chiang YP, Chuang CY, Lee CY. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem 2001; 276:13427-13432.
103. Schulz TF. Kaposi?s sarcoma-associated herpesvirus (human herpesvirus 8): epidemiology and pathogenesis. J Antimicrob Chemother 2000; 45 (Suppl T3):15-27.
104. Lee H, Guo J, Li M, Choi JK, DeMaria M, Rosenzweig M, Jung JU. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi?s sarcoma-associated herpesvirus. Mol Cell Biol 1998; 18:5219-5228.
105. Gao SJ, Boshoff C, Jayachandra S, Weiss RA, Chang Y, Moore PS. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997; 15:1979-1985.
106. Searles RP, Bergquam EP, Axthelm MK, Wong SW. Sequence and genomic analysis of a Rhesus macaque rhadinovirus with similarity to Kaposi?s sarcoma-associated herpesvirus/human herpesvirus 8. J Virol 1999; 73:3040-3053.
107. Caselli E, Menegazzi P, Bracci A, Galvan M, Cassai E, Di Luca D. Human herpesvirus-8 (Kaposi?s sarcoma-associated her-pesvirus) ORF50 interacts synergistically with the tat gene product in transactivating the human immunodeficiency virus type 1 LTR. J Gen Virol 2001; 82:1965-1970.
108. Hyun TS, Subramanian C, Cotter MA 2nd, Thomas RA, Robertson ES. Latency-associated nuclear antigen encoded by Kaposi?s sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells. J Virol 2001; 75:8761-8771.
109. Gius D, Laimins LA. Activation of human papillomavirus type 18 gene expression by herpes simplex virus type 1 viral transactivators and a phorbol ester. J Virol 1989; 63:555-563.
110. Vernon SD, Hart CE, Reeves WC, Icenogle JP. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res 1993; 27:133-145.
111. Tornesello ML, Buonaguro FM, Beth-Giraldo E, Giraldo G. Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression. Intervirology 1993; 36:57-64.
112. Dolei A, Curreli S, Marongiu P, Pierangeli A, Gomes E, Bucci M, et al. Human immunodeficiency virus infection in vitro activates naturally integrated human papillomavirus type 18 and induces synthesis of the L1 capsid protein. J Gen Virol 1999; 80 (Pt 11):2937-2944.
113. Kim RH, Yochim JM, Kang MK, Shin KH, Christensen R, Park NH. HIV-1 Tat enhances replicative potential of human oral keratinocytes harboring HPV-16 genome. Int J Oncol 2008; 33:777-782.
114. Arany I, Evans T, Tyring SK. Tissue specific HPV expression and downregulation of local immune responses in condylo-mas from HIV seropositive individuals. Sex Transm Infect 1998; 74:349-353.
115. Nyagol J, Leucci E, Onnis A, De Falco G, Tigli C, Sanseverino F, et al. The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther 2006; 5:684-690.
116. Barreto-de-Souza V, Pacheco GJ, Silva AR, Castro-Faria-Neto HC, Bozza PT, Saraiva EM, Bou-Habib DC. Increased Leish-mania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis. J Infect Dis 2006; 194:846-854.
117. Barreto-de-Souza V, Xavier Medeiros T, Machado Motta MC, Bou-Habib DC, Saraiva EM. HIV-1 infection and HIV-1 Tat protein permit the survival and replication of a nonpatho-genic trypanosomatid in macrophages through TGF-beta1 production. Microbes Infect 2008; 10:642-649.
118. Denis M. Tat protein from HIV-1 binds to Mycobacterium avium via a bacterial integrin. Effects on extracellular and intracellular growth. J Immunol 1994; 153:2072-2081.
119. Crowle AJ, Ross ER, Cohn DL, Gilden J, May MH. Comparison of the abilities of Mycobacterium avium and Mycobacterium intracellulare to infect and multiply in cultured human macrophages from normal and human immunodeficiency virus-infected subjects. Infect Immun 1992; 60:3697-3703.
120. Kitaura H, Ohara N, Kobayashi K, Yamada T. TNF-alpha-mediated activation of HIV-1 LTR in monocytoid cells by mycobacteria. FEMS Immunol Med Microbiol 2001; 31:97-103.
121. Toossi Z, Wu M, Islam N, Teixeira-Johnson L, Hejal R, Aung H. Transactivation of human immunodeficiency virus-1 in T-cells by Mycobacterium tuberculosis-infected mononuclear phagocytes. J Lab Clin Med 2004; 144:108-115.
122. Cheung BK, Lee DC, Li JC, Lau YL, Lau AS. A role for double-stranded RNA-activated protein kinase PKR in Mycobacter-ium-induced cytokine expression. J Immunol 2005; 175:7218-7225.
123. Lee DC, Cheung CY, Law AH, Mok CK, Peiris M, Lau AS. p38 mitogen-activated protein kinase-dependent hyperinduction of tumor necrosis factor alpha expression in response to avian influenza virus H5N1. J Virol 2005; 79:10147-10154.
124. Law AH, Lee DC, Cheung BK, Yim HC, Lau AS. Role for nonstructural protein 1 of severe acute respiratory syndrome coronavirus in chemokine dysregulation. J Virol 2007; 81:416-422.
125. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 2005; 102:17717-17722.
126. Gruber A, Lell CP, Speth C, Stoiber H, Lass-Florl C, Sonneborn A, et al. Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro. Immunology 2001; 104:455-461.
127. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous C. albicans mutants are aviru-lent. Cell 1997; 90:939-949.
128. Madhani HD, Fink GR. The control of filamentous differentiation and virulence in fungi. Trends Cell Biol 1998; 8:348-353.
129. Mitchell AP. Dimorphism and virulence in Candida albicans. Curr Opin Microbiol 1998; 1:687-692.
130. De Bernardis F, Chiani P, Ciccozzi M, Pellegrini G, Ceddia T, D?Offizzi G, et al. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun 1996; 64:466-471.
131. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993; 57:183-289.
132. Sweet SP, Cookson S, Challacombe SJ. Candida albicans isolates from HIV-infected and AIDS patients exhibit enhanced adherence to epithelial cells. J Med Microbiol 1995; 43:452-457.
133. O?Hara SP, Small AJ, Gajdos GB, Badley AD, Chen XM, Larusso NF. HIV-1 Tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against Cryptos-poridium parvum. J Infect Dis 2009; 199:1195-1204.
134. O?Hara SP, Small AJ, Nelson JB, Badley AD, Chen XM, Gores GJ, Larusso NF. The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apopto-sis in cholangiocytes via a Fas ligand-dependent mechanism. Infect Immun 2007; 75:684-696.
135. Mayer HB, Wanke CA, Du B, Hammer SM, Terwilliger EF. HIV-1 Tat modulates invasion by a bacterial enteric pathogen into a human intestinal cell line. AIDS 1995; 9:1237-1242.
136. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3:e2516.
137. Anselmi A, Vendrame D, Rampon O, Giaquinto C, Zanchetta M, De Rossi A. Immune reconstitution in human immunodeficiency virus type 1-infected children with different virolo-gical responses to antiretroviral therapy. Clin Exp Immunol 2007; 150:442-450.
138. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
139. Farizo KM, Buehler JW, Chamberland ME, Whyte BM, Froe-licher ES, Hopkins SG, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992; 267:1798-1805.
140. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4R T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-133.
141. Proctor RA. Bacterial sepsis in patients with acquired immunodeficiency syndrome. Crit Care Med 2001; 29:683-684.
142. Rosenberg AL, Seneff MG, Atiyeh L, Wagner R, Bojanowski L, Zimmerman JE. The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance. Crit Care Med 2001; 29:548-556.
143. Huang LM, Chao MF, Chen MY, Shih H, Chiang YP, Chuang CY, Lee CY. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem 2001; 276:13427-13432.
144. Cupelli LA, Hsu MC. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J Virol 1995; 69:2640-2643.
145. Hsu MC, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, et al. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 1991; 254:1799-1802.
146. Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, et al. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis 1995; 172:1246-1252.
147. Karn J. Tackling Tat. J Mol Biol 1999; 293:235-254.
148. Kalantari P, Narayan V, Henderson AJ, Prabhu KS. 15-Deoxy-Delta12, 14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification. FASEB J 2009; 23:2366-2373.
149. Rusnati M, Tulipano G, Urbinati C, Tanghetti E, Giuliani R, Giacca M, et al. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J Biol Chem 1998; 273:16027-16037.
150. Esquieu D, Peloponese JM, Opi S, Gregoire C, de Mareuil J, Watkins J, et al. Discovery of a Tat HIV-1 inhibitor through computer-aided drug design. Spectroscopy 2003; 17:639-645.
151. Demirhan I, Chandra A, Mueller F, Mueller H, Biberfeld P, Hasselmayer O, Chandra P. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi?s sarcoma. J Hum Virol 2000; 3:137-143.
152. Krone WJ, Debouck C, Epstein LG, Heutink P, Meloen R, Goudsmit J. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J Med Virol 1988; 26: 261-270.
153. Zagury JF, Sill A, Blattner W, Lachgar A, Le Buanec H, Richardson M, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1998; 1:282-292.
154. Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005; 191:1321-1324.
155. van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, de Wolf F, et al. Human immunodeficiency virus type 1 Rev-and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78 (Pt 8):1913-1918.
156. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001; 98:1781-1786.
157. Van Baalen CA, Schutten M, Huisman RC, Boers PH, Gruters RA, Osterhaus AD. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol 1998; 72:6851-6857.
158. Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, et al. Control of SHIV-89. 6P-infection of cyno-molgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999; 5:643-650.
159. Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S, Caputo A, et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomol-gus monkeys upon infection with simian/human
160. Caselli E, Betti M, Grossi MP, Balboni PG, Rossi C, Boarini C, et al. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J Immunol 1999; 162:5631-5638.
161. Goldstein G, Manson K, Tribbick G, Smith R. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 2000; 18:2789-2795.
162. Allen TM, Mortara L, Mothe BR, Liebl M, Jing P, Calore B, et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002; 76:4108-4112.
163. Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, et al. Long-term protection against SHIV89. 6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004; 22:3258-3269.
164. Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, et al. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 2009; 4:195-204.
165. Campbell GR, Loret EP. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology 2009; 6:50.
166. Campbell GR, Senkaali D, Watkins J, Esquieu D, Opi S, Yirrell DL, et al. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine 2007; 25:8441-8447.
167. Gregoire CJ, Loret EP. Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates. J Biol Chem 1996; 271:22641-22646.
168. Opi S, Peloponese JM Jr, Esquieu D, Campbell G, de Mareuil J, Walburger A, et al. Tat HIV-1 primary and tertiary structures critical to immune response against nonhomologous variants. J Biol Chem 2002; 277:35915-35919.
169. Watkins JD, Lancelot S, Campbell GR, Esquieu D, de Mareuil J, Opi S, et al. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. Retrovirology 2006; 3:8.